CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$56.22 USD
+0.55 (0.99%)
Updated May 17, 2024 04:00 PM ET
After-Market: $55.90 -0.32 (-0.57%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Brokerage Reports
CRISPR Therapeutics AG [CRSP]
Reports for Purchase
Showing records 161 - 180 ( 209 total )
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Synopsis of Our Recent Webinar with Management
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Reminder to Register for Our Call with Management on July 15 at 2 PM ET
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Register Now to Join Our Call with CEO and CFO on July 15 at 2PM ET
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Scientific Presentations Highlight Various Allogeneic CAR Constructs
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
New Trial Posted Last Night on Clinicaltrials.gov for Solid Tumor Therapy
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Updated Model with $105 PT on the Heels of EHA Data
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
CRISPR Cuts Away Troubling Inherited Hemoglobin Diseases
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
EHA Presentation on a Third Beta-thal Patient Treated with Crispr-Cas9. And There Is AACR.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
See Our Highlights from AACR II (June 22-24, 2020) Meeting Abstracts
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department